49 results about "Tocophersolan" patented technology

The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.

A method of making an emulsion of tocopherol incorporating a co-solvent and, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans by various routes, is disclosed. Also included in the emulsion is PEGylated vitamin E. PEGylated α-tocopherol includes polyethylene glycol subunits attached by a succinic acid diester at the ring hydroxyl of vitamin E and serves as a primary surfactant, stabilizer and a secondary solvent in emulsions of α-tocopherol.

The present invention relates to a deterioration preventive for a flavor component, which is an oil-in-water and/or -polyhydric alcohol type emulsion, comprising an extracted tocopherol, wherein d-δ-tocopherol is contained in an amount of 45% by weight or more of a total tocopherol, ferulic acid and/or a derivative thereof, and a polyglycerol fatty acid ester; a deterioration preventive for a flavor component, which is an oil-in-water and/or -polyhydric alcohol type emulsion, comprising (A) the above-mentioned extracted tocopherol, (B) ferulic acid and/or a derivative thereof, and (C) an emulsifying agent having an HLB of 9 or more; a flavor for foodstuff, comprising the above-mentioned deterioration preventive; an emulsion flavor for foodstuff, comprising the above-mentioned extracted tocopherol, a catechin; and a polyglycerol fatty acid ester; and foodstuff comprising the above-mentioned deterioration preventive for a flavor component, the above-mentioned flavor for foodstuff, or the above-mentioned emulsion flavor for foodstuff.

Compositions comprising an RNA interference (RNAi) compound complexed to or encapsulated by lipid particles are provided. The lipid particle is a lipid nanoparticle, a liposome or a combination thereof. The lipid particle comprises a cationic lipid, a phospholipid, a sterol or a tocopherol or a derivative thereof, and a conjugated lipid. The invention also provides methods for treating pulmonary diseases or disorders such as pulmonary fibrosis and sarcoidosis using the compositions comprising the RNAi-lipid particles of the invention. The methods comprise administering one or more of the RNAi compositions to the lungs of the patient in need thereof via an inhalation delivery device, for example, a nebulizer, dry powder inhaler, or a metered dose inhaler.

Disclosed are nutritional formulas generally, and infant formulas specifically, including a combination of RRR-alpha tocopherol, LC-PUFAs, and optionally vitamin C. The combination enhances brain development and improves cognitive performance in an individual, and specifically in an infant.

An oral care composition, such as a dentifrice composition, which provides enhanced anti-gingivitis efficacy is disclosed. The composition includes a tocopherol component which consists of about 10% to about 90% of gamrnma tocopherol, with the balance of the components selected from alpha tocopherol, beta tocopherol, delta tocopherol, and mixtures thereof.

Antioxidant formulations containing new active molecules with tocopherols are disclosed. The best performing formulas contain extracts of green tea that are oil soluble, extracts of rosemary, extracts of spearmint and tocotrienols. Interestingly, the amount of tocopherols in formulas could be reduced by 50% in this diet when the other actives were increased accordingly.

This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant vitamin E analogue, such as α-tocopheryl succinate, α-tocopheryl maleate, α-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (α-tocopheryloxyacetic acid).

A pharmaceutical composition is described comprising sucralfate gel, PVA and optionally a vegetable product comprising tocotrienols and tocopherols. In particular, this composition proved to be suitable for being sprayed, and is advantageously used in the treatment of skin lesions, even deep lesions, such as second-degree burns.

At least three component, body-implantable, absorbable, biocompatible, putty, and non-putty pain-relieving compositions for use in surgery comprising in intimate admixture: an analgesic having local pain-relieving activity for internal relief of pain, a finely powdered bulking material, preferably less than 50 microns, e.g. the metal salts of fatty acid, hydroxyapatite, DBM, polyglycolide, polylactide, polycaprolactones, absorbable glasses, gelatin, collagens, mono, and polysaccharides starches.

An organic liquid capable of solubilizing, dispensing or suspending the analgesic, such as esters of monohydric alcohols with aliphatic monocarboxylic acids; C₂-C₁₈ monohydric alcohols with polycarboxylic acids; C₈-C₃₀ monohydric alcohols; tocopherol and esters thereof with mono or polycarboxylic acids; free carboxylic acids such as oleic, capric, and lauric; dialkyl ethers and ketones; polyhydroxy compounds and esters and ethers thereof; random or block copolymers of ethylene oxide and propylene oxide.

A method of enhancing the bioavailability of a lipid-soluble nutrient, such as DHA, arachidonic acid, tocopherol, and carotenoids, in a newborn or preterm infant is disclosed. In this method, the lipid-soluble nutrient is administered in a nutritional product (such as an infant formula) to a preterm or newborn infant. The nutritional product comprises (a) an effective amount of the lipid-soluble nutrient; and (b) a fatty component comprising a combination of: (i) at least 6 g/l predigested fat, wherein the predigested fat includes at least one of: monoglycerides, free fatty acids, or a combination of monoglycerides and free fatty acids, and (ii) at least 1.44 g/l phospholipid. A method of enhancing cognition in newborn or preterm infants utilizing the nutritional product is also disclosed.

The invention belongs to the field of cosmetics, and in particular relates to whitening cream and a preparation method thereof. The whitening cream is prepared from the following raw materials: an emulsifier, tocopherol (vitamin E), laurocapram, water, EDTA disodium, xanthan gum, propylene glycol, glycerinum, polyacrylamide, C13-14 isoparaffin, laurinol polyether-7, 3-o-ethyl ascorbic acid, a double-layered surfactant, magnesium phosphate coating ascorbic acid and a preservative. As the whitening cream prepared by the proper amount of raw materials is free of unclear components, the whiteningcream is good in safety, high in degree of recognition of consumers and free of side effects compared with common whitening cream products. The whitening cream is good in whitening effect, can enhancethe brightness of skin effectively if being used for a long time, alleviates the synthetic speed of melanin effectively, and also plays the roles of complementing water, moisturizing, protecting skinand whitening. The whitening cream is safe and non-irritant to human skin, and is suitable for various crowds.

A solubilizing agent of the formula €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ X-OOC-(CH 2 ) n -COO-Y wherein X is a member selected from campesterol, sitosterol, ergosterol and stigmasterol; Y is a member selected from polyalcohol, polyether, polyanion, polycation, polyphosphoric acid, polyamine, polysaccharide, polyhydroxy compound and polylysine, and derivatives thereof; and n is an integer selected from 0 to 18. The solubilizing agent may be included in a water-soluble composition comprising a bioactive lipophilic compound and the solubilizing agent.

The invention discloses a nutritional agent with noise reduced hearing loss resistance. The nutritional agent is prepared from the following raw materials in parts by weight: 600-1000 parts of N-acetyl-L-cysteine, 1-4 parts of vitamin A, 1-5 parts of vitamin B1, 1-5 parts of vitamin B2, 1-10 parts of vitamin B6, 0.01-0.05 part of vitamin B12, 60-1000 parts of vitamin C, 15-300 parts of vitamin E which is based on alpha-totaxin, 50-400 parts of magnesium and 79-3175 parts of food acceptable accessories. Experiment data displays that the nutritional agent has remarkable effect of preventing and controlling the noise induced hearing loss. The nutritional agent can be used for enhancing the anti-oxidation ability of the organism and lightening the exitotoxicity damage, has the characteristics of being remarkable in curative effect, low in potential toxicity and low in cost, and is suitable for the noise reduced hearing loss protection and daily nutrient supplementation of people who live and work in the environment with continuous exposed high-intensity noise.

A formulation includes a continuous hydrophobic phase, a hydrophilic phase, at least one hydrophilic compound substantially dissolved in the hydrophilic phase, and a stabilizing component. The stabilizing component can contain D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) and/or at least one emulsifier having a hydrophilic-lipophilic balance (HLB) value of at least 10. In one alternative, the stabilizing component contains a first, polysorbate emulsifier having an HLB value of at least 10, and a second emulsifier having an HLB value of less than 10.

Certain dermatological formulations for direct skin application that correct for hyperpigmentation effects are provided. Such formulations include a number of different compounds that work synergistically to effectuate multiple and varied pathways to pigment removal and/or brightening within the dermal layer. The ability to do so without the necessity for hydroquinone, and thus with a suitable composition that is safe for handling and utilization by pregnant and nursing women, is accorded through a combination of specific ingredients in limited proportional ranges, as well. Such ingredients include kojic acid, niacinamide, sodium hyaluraonate, tocopherol, and licorice extract in very narrow ranges proportionally within an aqueous serum. The method of manufacture and use thereof such formulations are encompassed within the invention as well.

The present disclosure is directed to a nitrocellulose-based propellant composition comprising: (a) a nitrate ester based propellant comprising nitrocellulose; and (b) a stabiliser consisting of a tocopherol compound with a general formula (I),

wherein: X is oxygen; R¹ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, ester, saccharide, alkoxy-linked saccharide, alcohol, and ethers; R² is selected from the group consisting of hydrogen methyl, benzyl carboxylic acid, benzyl carboxylate, benzylester and saccharide; R³ is selected from the group consisting of hydrogen, methyl, benzyl carboxylic acid, benzyl carboxylate, benzylester and saccharide; R⁴ is selected from the group consisting of methyl, benzyl carboxylic acid, benzyl carboxylate, benzylester and saccharide; and R⁵ is selected from the group consisting of alkyl and alkenyl.

The invention relates to an extraction method of a tocopherol intermediate, belonging to the technical field of organic complexing extraction. The tocopherol intermediate is a product obtained after aminomethylation reaction of non-D-alpha-tocopherol in a tocopherol concentrated solution. The tocopherol concentrated solution contains higher-content mixed tocopherol (D-alpha, beta, gamma and delta-tocopherol), also contains a great amount of glyceride, fatty acid methyl ester, sterol ester and other impurities, and the preparation of high-content D-alpha-tocopherol is hindered by the existence of the impurities. The boiling points of the impurities are close to that of tocopherol, therefore, the impurities cannot be separated from tocopherol by distilling and other methods. The non-D-alpha-tocopherol intermediate is a tertiary amine substance, has certain alkalinity, and can be combined with an acid to form a salt, and glyceride and other impurities are easy to dissolve in an organic solvent. According to the invention, the tocopherol intermediate is extracted from glyceride and other impurities by a liquid-liquid extraction method, and the obtained non-D-alpha-tocopherol intermediate is almost pure, thus the purpose of purification is achieved.

The invention discloses a preparation method of d-alpha-tocopherol polyethylene glycol succinate. The preparation method comprises the following steps: by taking Merrifield resin and PEG1,000 as raw materials and alkali as a catalyst, performing reaction at 45-135 DEG C in an organic solvent to obtain resin loaded with PEG1,000; under the action of the catalyst, enabling the resin loaded with PEG1,000 and d-alpha-tocopherol succinate to be subjected to water diversion reflux reaction to obtain resin loaded with TPGS; and soaking the resin loaded with TPGS in toluene, then adding ethanol, palladium on carbon and phosphopyridoxal, and performing stirring reaction at 100-110 DEG C for 24 hours in hydrogen gas of 0.8-1.5MPa to obtain the d-alpha-tocopherol polyethylene glycol succinate. By adopting the synthetic method disclosed by the invention, the yield of TPGS is as high as 99%, the monoester content of TPGS is 99%, and the diester content of TPGS is 0.